Bayesian Capital Management, LP Eagle Pharmaceuticals, Inc. Transaction History

Bayesian Capital Management, LP

  • $838 Million
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2019

May 14, 2019
SELL
$38.66 - $51.82 $210,078 - $281,589
-5,434 Closed
0 $0
Q4 2018

Feb 13, 2019
BUY
$36.72 - $67.73 $199,536 - $368,044
5,434 New
5,434 $219,000
Q1 2018

May 15, 2018
SELL
$52.16 - $66.86 $272,848 - $349,744
-5,231 Closed
0 $0
Q4 2017

Feb 12, 2018
BUY
$49.6 - $60.87 $259,457 - $318,410
5,231
5,231 $279,000

Others Institutions Holding EGRX

# of Institutions
70
Shares Held
8.59M
Call Options Held
1M
Put Options Held
100
View Full List

About EAGLE PHARMACEUTICALS, INC.

EGRX Quotes by TradingView
  • Ticker EGRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 13,015,900
  • Market Cap $9.5M
  • Description
  • Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...
More about EGRX
Track This Portfolio

Track Bayesian Capital Management, LP Portfolio

Follow Bayesian Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bayesian Capital Management, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email